Searching for New Tools to Counteract the <i>Helicobacter pylori</i> Resistance: The Positive Action of Resveratrol Derivatives
The drug-resistance phenomenon in <i>Helicobacter pylori</i> underlines the need of novel strategies to improve the eradication rate including alternative treatments combining antibiotic and non-antibiotic compounds with synergistic action. In this study, the antibacterial (MIC/MBC) and...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Book |
| Published: |
MDPI AG,
2020-12-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The drug-resistance phenomenon in <i>Helicobacter pylori</i> underlines the need of novel strategies to improve the eradication rate including alternative treatments combining antibiotic and non-antibiotic compounds with synergistic action. In this study, the antibacterial (MIC/MBC) and anti-virulence effects (biofilm reduction and swarming motility inhibition) of resveratrol-RSV and new synthetized RSV-phenol derivatives, with a higher bioavailability, alone and combined with levofloxacin-LVX were evaluated against resistant <i>H. pylori</i> clinical strains. The experiments were confirmed in vivo using the <i>Galleria mellonella</i> model. Among the studied RSV derivatives, RSV-3 and RSV-4 possessed higher antibacterial activity with respect to RSV (MICs from 6.25 to 200 µg/mL and from 3.12 to 200 µg/mL, respectively). RSV, RSV-3, and RSV-4 were able to synergize with LVX restoring its effect in two out of seven clinical resistant strains tested for the study. RSV, RSV-3, and RSV-4, alone and with LVX at sub-MIC and sub-synergistic concentrations, significantly reduced the biofilm formation. Moreover, RSV-3 and RSV-4 reduced the <i>H. pylori</i> swarming motility on soft agar. RSV, RSV-3, and RSV-4 were non-toxic for <i>G. mellonella</i> larvae and displayed a protective effect against <i>H. pylori</i> infection. Overall, RSV-phenol derivatives should be considered interesting candidates for innovative therapeutic schemes to tackle the <i>H. pylori</i> antibiotic resistance. |
|---|---|
| Item Description: | 10.3390/antibiotics9120891 2079-6382 |